var data={"title":"Dornase alfa: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dornase alfa: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6057?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dornase-alfa-drug-information\" class=\"drug drug_general\">see &quot;Dornase alfa: Drug information&quot;</a> and <a href=\"topic.htm?path=dornase-alfa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dornase alfa: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161836\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pulmozyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161837\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pulmozyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058062\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Enzyme, Inhalant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Mucolytic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058057\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=dornase-alfa-drug-information\" class=\"drug drug_general\">see &quot;Dornase alfa: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">\n      <b>Cystic fibrosis: </b></p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Infants and Children &lt;2 years; <i>Symptomatic patients:</i> Limited data available (Borowitz 2009; McKenzie 2007): Inhalation: Nebulization: 2.5 mg/day through selected nebulizers in conjunction with Pulmo-Aide, Pari-Proneb, Mobilaire, Porta-Neb, or Pari Baby compressor system or eRapid Nebulizer System (Berge 2003)</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Children 2 to &lt;5 years; <i>Acute exacerbations or chronic use in select patients:</i> Limited data available (Lahiri 2016; McKenzie 2007): Inhalation: Nebulization: 2.5 mg/day through selected nebulizers in conjunction with Pulmo-Aide, Pari-Proneb, Mobilaire, Porta-Neb, or Pari Baby compressor system or eRapid Nebulizer System (Nasr 2001)</p>\n    <p style=\"text-indent:-4em;margin-left:8em;\">Children &ge;5 years and Adolescents; <i>Chronic therapy:</i> Inhalation: Nebulization: 2.5 mg/day through selected nebulizers in conjunction with a Pulmo-Aide, Pari-Proneb, Mobilaire, Porta-Neb, or Pari Baby compressor system or the eRapid Nebulizer System; chronic daily use in cystic fibrosis patients &ge;6 years of age (Mogayzel 2013). Some patients may benefit from twice daily dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhinosinusitis, chronic; secondary to cystic fibrosis</b>: Limited data available: Children &ge;5 years and Adolescents: Inhalation: Intranasal: 2.5 mg/day nebulized intranasal with the Pari Sinus; dosing based in double-blind, placebo-controlled cross-over trial in 23 subjects (age range: 5 to 67 years) which showed improvement of primary nasal symptoms compared to placebo (isotonic saline); treatments were well tolerated, nasal bleeding reported in two patients (Mainz 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161821\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pulmozyme: 1 mg/mL (2.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161808\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058065\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebulization: Should not be diluted or mixed with any other drugs in the nebulizer, this may inactivate the drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Nebulize for 4 minutes per nostril using Pari Sinus compressor and Pari LC Sprint Star (Mainz 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161833\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) in protective foil to protect from light. Refrigerate during transport and do not expose to room temperatures for &ge;24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058064\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of cystic fibrosis (CF) patients to reduce the frequency of respiratory infections that require parenteral antibiotics in patients with FVC &ge;40% of predicted; in conjunction with standard therapies to improve pulmonary function (FDA approved in ages &ge;5 years and adults); has also been used intranasally to reduce signs and symptoms associated with rhinosinusitis in patients with CF</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161875\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were similar in children using the PARI BABY&trade; nebulizer (facemask as opposed to mouthpiece) with the addition of cough.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Chest pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Dyspepsia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immunologic: Antibody development (to dornase alfa)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cough (PARI-BABY nebulizer facemask), decrease in forced vital capacity (&ge;10% decrease of predicted), dyspnea, laryngitis, pharyngitis, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Headache, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161826\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to dornase alfa, Chinese hamster ovary cell products, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161812\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Decreased pulmonary function: In patients with pulmonary function &lt;40% of normal, dornase alfa does not significantly reduce the risk of respiratory infections that require parenteral antibiotics. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Safety studies included children &ge;3 months, however experience is limited in children &lt;5 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25856119\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\"> Use with caution in infants and children &lt;5 years of age; safety studies included infants down to 3 months; limit use to those infants and children &lt;5 years to those with potential for benefit in pulmonary function or in risk of respiratory tract infection. Some adverse effects were reported more frequently in infants and children &lt;5 years of age than older children (5 to 10 years of age) including: Cough (45% vs 30%) and rhinitis (35% vs 27%). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299229\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6219980\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13249&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5131960\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161811\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The hallmark of cystic fibrosis lung disease is the presence of abundant, purulent airway secretions composed primarily of highly polymerized DNA. The principal source of this DNA is the nuclei of degenerating neutrophils, which is present in large concentrations in infected lung secretions. The presence of this DNA produces a viscous mucous that may contribute to the decreased mucociliary transport and persistent infections that are commonly seen in this population. Dornase alfa is a deoxyribonuclease (DNA) enzyme produced by recombinant gene technology. Dornase selectively cleaves DNA, thus reducing mucous viscosity and as a result, airflow in the lung is improved and the risk of bacterial infection may be decreased.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161825\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Nebulization: Enzyme levels are measured in sputum in ~15 minutes and decline rapidly thereafter </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Sputum concentrations decline within 2 hours of inhalation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161828\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pulmozyme Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (2.5 mL): $137.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161829\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Pulmozym (UA);</li>\n      <li>Pulmozyme (AR, AT, AU, BB, BE, BG, BM, BR, BS, BZ, CH, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, GY, HN, HR, HU, IE, IL, IS, IT, JM, JP, KW, LB, LT, LU, LV, MT, MX, NI, NL, NO, NZ, PA, PE, PL, PT, RO, RU, SE, SI, SK, SR, SV, TR, TT, UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Berge MT, Wiel Ev, Tiddens HA, Merkus PJ, Hop WC, de Jongste JC. DNase in stable cystic fibrosis infants: a pilot study. <i>J Cyst Fibros</i>. 2003;2(4):183-188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-pediatric-drug-information/abstract-text/15463871/pubmed\" target=\"_blank\" id=\"15463871\">15463871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borowitz D, Robinson KA, Rosenfeld M, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. <i>J Pediatr</i>. 2009;155(6 Suppl):S73-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-pediatric-drug-information/abstract-text/19914445/pubmed\" target=\"_blank\" id=\"19914445\">19914445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs HJ, Borowitz DS, Christiansen DH, et al, &ldquo;Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients With Cystic Fibrosis,&rdquo; <i>N Engl J Med</i>, 1994, 331(10):637-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-pediatric-drug-information/abstract-text/ 7503821 /pubmed\" target=\"_blank\" id=\" 7503821 \"> 7503821 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lahiri T, Hempstead SE, Brady C, et al. Clinical Practice Guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. <i>Pediatrics</i>. 2016;137(4).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-pediatric-drug-information/abstract-text/27009033/pubmed\" target=\"_blank\" id=\"27009033\">27009033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mainz JG, Schien C, Schiller I, et al. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. <i>J Cyst Fibros</i>. 2014;13(4):461-470.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-pediatric-drug-information/abstract-text/24594542/pubmed\" target=\"_blank\" id=\"24594542\">24594542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McKenzie SG, Chowdhury S, Strandvik B, et al. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. <i>Pediatr Pulmonol</i>. 2007;42(10):928-937.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-pediatric-drug-information/abstract-text/17726701/pubmed\" target=\"_blank\" id=\"17726701\">17726701</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. <i>Am J Respir Crit Care Med</i>. 2013;187(7):680-689.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-pediatric-drug-information/abstract-text/23540878/pubmed\" target=\"_blank\" id=\"23540878\">23540878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mueller GA, Rubins G, Wessel D, et al, &ldquo;Effects of Dornase Alfa on Pulmonary Function Tests in Infants with Cystic Fibrosis,&rdquo; <i>Am J Respir Crit Care Med</i>, 1996, 153:A70.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. <i>Pediatr Pulmonol</i>. 2001;31(5):377-382.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-pediatric-drug-information/abstract-text/11340684/pubmed\" target=\"_blank\" id=\"11340684\">11340684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pulmozyme (dornase alfa) [prescribing information]. South San Francisco, CA: Genentech, Inc; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rock M, Kirchner K, McCubbin M, et al, &ldquo;Aerosol Delivery and Safety of rhDNASE in Young Children With Cystic Fibrosis: A Bronchoscopic Study,&rdquo; <i>Pediatr Pulmonol</i>, 1996, 13(Suppl):A268.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suri R, Metcalfe C, Lees B, et al, &quot;Comparison of Hypertonic Saline and Alternate-Day or Daily Recombinant Human Deoxyribonuclease in Children With Cystic Fibrosis: A Randomised Trial,&quot; <i>Lancet</i>, 2001, 358(9290):1316-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-pediatric-drug-information/abstract-text/11684212/pubmed\" target=\"_blank\" id=\"11684212\">11684212</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suri R, &quot;The Use of Human Deoxyribonuclease (rhDNase) in the Management of Cystic Fibrosis,&quot; <i>BioDrugs</i>, 2005, 19(3):135-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-pediatric-drug-information/abstract-text/15984899 /pubmed\" target=\"_blank\" id=\"15984899 \">15984899 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagener JS, Rock MJ, McCubbin MM, et al, &quot;Aerosol Delivery and Safety of Recombinant Human Deoxyribonuclease in Young Children With Cystic Fibrosis: A Bronchoscopic Study. Pulmozyme Pediatric Broncoscopy Study Group,&quot; <i>J Pediatr</i>, 1998, 133(4):486-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dornase-alfa-pediatric-drug-information/abstract-text/9787685/pubmed\" target=\"_blank\" id=\"9787685\">9787685</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13249 Version 78.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F161836\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F161837\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058062\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058057\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F161821\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F161808\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058065\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F161833\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058064\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F161875\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F161826\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F161812\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25856119\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299229\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6219980\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5131960\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F161811\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F161825\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F161828\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F161829\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13249|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dornase-alfa-drug-information\" class=\"drug drug_general\">Dornase alfa: Drug information</a></li><li><a href=\"topic.htm?path=dornase-alfa-patient-drug-information\" class=\"drug drug_patient\">Dornase alfa: Patient drug information</a></li></ul></div></div>","javascript":null}